Background parenchymal enhancement and uptake as breast cancer imaging biomarkers: A state-of-the-art review

Ethan Bauer, Miri Sklair Levy, Liran Domachevsky, Debbie Anaby, Noam Nissan

Research output: Contribution to journalReview articlepeer-review

Abstract

Within the past decade, background parenchymal enhancement (BPE) and background parenchymal uptake (BPU) have emerged as novel imaging-derived biomarkers in the diagnosis and treatment monitoring of breast cancer. Growing evidence supports the role of breast parenchyma vascularity and metabolic activity as probable risk factors for breast cancer development. Furthermore, in the presence of a newly-diagnosed breast cancer, added clinically-relevant data was surprisingly found in the respective imaging properties of the non-affected contralateral breast. Evaluation of the contralateral BPE and BPU have been found to be especially instrumental in predicting the prognosis of a patient with breast cancer and even anticipating their response to neoadjuvant chemotherapy. Simultaneously, further research has found a link between these two biomarkers, even though they represent different physical properties. The aim of this review is to provide an up to date summary of the current clinical applications of BPE and BPU as breast cancer imaging biomarkers with the hope that it propels their further usage in clinical practice.

Original languageEnglish
Pages (from-to)41-50
Number of pages10
JournalClinical Imaging
Volume83
DOIs
StatePublished - Mar 2022

Keywords

  • BPE
  • BPU
  • Contralateral breast
  • Imaging biomarkers

Fingerprint

Dive into the research topics of 'Background parenchymal enhancement and uptake as breast cancer imaging biomarkers: A state-of-the-art review'. Together they form a unique fingerprint.

Cite this